CN120501855A - 给予抗cd38抗体以治疗多发性骨髓瘤的方法 - Google Patents

给予抗cd38抗体以治疗多发性骨髓瘤的方法

Info

Publication number
CN120501855A
CN120501855A CN202510468038.XA CN202510468038A CN120501855A CN 120501855 A CN120501855 A CN 120501855A CN 202510468038 A CN202510468038 A CN 202510468038A CN 120501855 A CN120501855 A CN 120501855A
Authority
CN
China
Prior art keywords
antibody
infusion
satuo
patients
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510468038.XA
Other languages
English (en)
Chinese (zh)
Inventor
F·坎帕纳·桑布拉诺
H·奥达
S·马里昂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis US LLC
Original Assignee
Sanofi Aventis US LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis US LLC filed Critical Sanofi Aventis US LLC
Publication of CN120501855A publication Critical patent/CN120501855A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202510468038.XA 2019-05-14 2020-05-13 给予抗cd38抗体以治疗多发性骨髓瘤的方法 Pending CN120501855A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201962847825P 2019-05-14 2019-05-14
US62/847,825 2019-05-14
US201962860739P 2019-06-12 2019-06-12
US62/860,739 2019-06-12
US201962899088P 2019-09-11 2019-09-11
US62/899,088 2019-09-11
EP20305223.8 2020-03-03
EP20305223 2020-03-03
PCT/US2020/032754 WO2020232173A1 (en) 2019-05-14 2020-05-13 Methods of administering anti-cd38 antibody to treat multiple myeloma
CN202080049892.8A CN114080233A (zh) 2019-05-14 2020-05-13 给予抗cd38抗体以治疗多发性骨髓瘤的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080049892.8A Division CN114080233A (zh) 2019-05-14 2020-05-13 给予抗cd38抗体以治疗多发性骨髓瘤的方法

Publications (1)

Publication Number Publication Date
CN120501855A true CN120501855A (zh) 2025-08-19

Family

ID=71094805

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510468038.XA Pending CN120501855A (zh) 2019-05-14 2020-05-13 给予抗cd38抗体以治疗多发性骨髓瘤的方法
CN202080049892.8A Pending CN114080233A (zh) 2019-05-14 2020-05-13 给予抗cd38抗体以治疗多发性骨髓瘤的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080049892.8A Pending CN114080233A (zh) 2019-05-14 2020-05-13 给予抗cd38抗体以治疗多发性骨髓瘤的方法

Country Status (15)

Country Link
US (1) US20210171650A1 (cg-RX-API-DMAC7.html)
EP (1) EP3969004A1 (cg-RX-API-DMAC7.html)
JP (2) JP7801132B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220008305A (cg-RX-API-DMAC7.html)
CN (2) CN120501855A (cg-RX-API-DMAC7.html)
AU (1) AU2020274169A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022503A2 (cg-RX-API-DMAC7.html)
CA (1) CA3140034A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021016606A2 (cg-RX-API-DMAC7.html)
IL (1) IL287832A (cg-RX-API-DMAC7.html)
MA (1) MA55967A (cg-RX-API-DMAC7.html)
MX (1) MX2021013910A (cg-RX-API-DMAC7.html)
SG (1) SG11202112513YA (cg-RX-API-DMAC7.html)
TW (1) TW202108624A (cg-RX-API-DMAC7.html)
WO (1) WO2020232173A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
MX2020007429A (es) 2018-01-12 2020-10-15 Takeda Pharmaceuticals Co Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
BR112021000065A2 (pt) * 2018-07-10 2021-04-06 Sanofi Terapias de combinação contra câncer direcionando cd38 e tgf-beta
WO2020250033A1 (en) * 2019-06-10 2020-12-17 Takeda Pharmaceutical Company Limited Combination therapies using cd-38 antibodies
IL302640A (en) * 2020-11-03 2023-07-01 Sanofi Aventis Us Llc Use of isatuximab for the treatment of multiple myeloma
KR20240024047A (ko) 2021-04-08 2024-02-23 아티바 바이오테라퓨틱스, 인크. Nk 세포와 cd38 표적 항체를 이용한 암 치료 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US10342869B2 (en) * 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
EP3313441B1 (en) * 2015-06-24 2024-02-21 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
IL285110B2 (en) * 2019-01-28 2025-11-01 Sanofi Sa Methods of treating multiple myeloma

Also Published As

Publication number Publication date
JP7801132B2 (ja) 2026-01-16
WO2020232173A1 (en) 2020-11-19
US20210171650A1 (en) 2021-06-10
TW202108624A (zh) 2021-03-01
EP3969004A1 (en) 2022-03-23
MA55967A (fr) 2022-03-23
CO2021016606A2 (es) 2022-04-29
CA3140034A1 (en) 2020-11-19
AU2020274169A1 (en) 2022-01-20
JP2025166108A (ja) 2025-11-05
SG11202112513YA (en) 2021-12-30
JP2022532356A (ja) 2022-07-14
IL287832A (en) 2022-01-01
CN114080233A (zh) 2022-02-22
BR112021022503A2 (pt) 2021-12-28
MX2021013910A (es) 2022-03-11
KR20220008305A (ko) 2022-01-20

Similar Documents

Publication Publication Date Title
JP7801132B2 (ja) 抗cd38抗体を投与して多発性骨髄腫を処置する方法
US20240190984A1 (en) Methods of treating multiple myeloma
JP2019514889A (ja) 抗pd−l1および抗ctla−4抗体の共製剤を含む組成物
CN114007700A (zh) 抗FcRn抗体在治疗天疱疮和类天疱疮疾病中的用途
US20190194311A1 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
US20230212292A1 (en) Use of anti-pd-1 antibody in treating neuroendocrine tumors
EP3897718A1 (en) Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant
TW202541838A (zh) 抗cd38抗體在治療新診斷的多發性骨髓瘤中之用途
CN113993543B (zh) 使用抗cd38抗体的组合疗法
JP2021505545A (ja) 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法
JP2023505219A (ja) 再発性および/または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用
CA3048245A1 (en) Methods of administering anti-cd38 antibody
CA3048198A1 (en) Methods of treating multiple myeloma
RU2838203C2 (ru) Способы лечения множественной миеломы
WO2025155607A1 (en) Methods of treating urothelial carcinoma with a pd-1 axis binding antagonist and an rna vaccine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination